ATS2017 5月24日

Facebookページで取り上げたATSニュースのメモです。

URL:Facebookサイト「呼吸器内科医」 https://www.facebook.com/pulmonarist



<5月24日> News48~News57

・A7119 -M. Koslow, et al. Rheumatoid Pulmonary Nodules: Clinical and Imaging Features
・A7009 -K. J. Cummings, et al. Occupational Contribution to Idiopathic Pulmonary Fibrosis
・A7010 - T. M. Maher, et al. A Randomised, Placebo-Controlled, Double-Blind, Repeat Dose Escalation Study with Omipalisib (GSK2126458) in Patients with Idiopathic Pulmonary Fibrosis (IPF)
・A7012 -T. Luckhardt, et al. Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis Patients
・A7409 -M. Mohning, et al. Duration of Rheumatoid Arthritis and the Risk of Developing Interstitial Lung Disease
・A7007 -H. E. Jo, et al. Biomarkers Can Predict Disease Progression in Idiopathic Pulmonary Fibrosis: Analysis from the Australian IPF Registry
・A7422 - M. Orcholski, et al. Tankyrase Inhibitors: A Potential Novel Therapy for LAM/TSC
・A7411 - J. Lee, et al. Clinical Characteristics and Prognosis of Interstitial Pneumonia with Autoimmune Features
・Nathan SD, et al. Effect of Pirfenidone on All-Cause Mortality (ACM) and Forced Vital Capacity (FVC) in Idiopathic Pulmonary Fibrosis (IPF) Patients With Low FVC and/or Low DLCO: Analysis of Pooled Data From ASCEND and CAPACITY.
・Glassberg MK, et al. Effect of Pirfenidone on Breathlessness as Measured by the UCSD SOBQ Score in Patients With Idiopathic Pulmonary Fibrosis (IPF) With Moderate Lung Function Impairment
・Lederer D, et al. Effect of pirfenidone on a novel definition of progression-free survival (PFS) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from Phase III trials
・Lalla D, et al. Pirfenidone and Nintedanib compliance and persistence in a real-world setting.
・A5747-G. Chupp, et al. Post-Approval Study for Bronchial Thermoplasty (BT): Results to 2 Years


by otowelt | 2017-05-25 07:54 | 呼吸器その他

<< ATS2017閉幕 ATS2017 5月23日 >>